Oral Cancer Clinical Trials in Georgia

Cancer Type = Oral Cancer

Cancer Type = Oral Cancer

There are currently 12 active Oral Cancer clinical trials in Georgia.
2.
A Phase I / II Study of Concurrent Cetuximab and Nivolumab in Patients with Recurrent and / or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Oral Cancer, Unknown Primary
NCI ID
NCT03370276
Protocol IDs
MCC-19178
NCI-2017-02373
3.
A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Cancer Type
Head and Neck Cancer, Oral Cancer
NCI ID
NCT02567422
Protocol IDs
9950
NCI-2015-01643
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients with RM SCCHN Who Have Failed Platinum Based Therapy
Cancer Type
Head and Neck Cancer, Oral Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03468218
Protocol IDs
Winship4234-17
NCI-2017-02419
IRB00100269
5.
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Oral Cancer
NCI ID
NCT01141231
Protocol IDs
97115
NCI-2011-02073
CDR0000674208
WF 97115
WFU-97115
MDA-04-01
6.
A Prospective, Randomized, Double-Blind, Placebo-Controlled Pilot Study of Single-Dose Intraoperative Ketamine for the Prevention of Delirium in Otolaryngeal Cancer Surgery Patients
Cancer Type
Head and Neck Cancer, Oral Cancer
NCI ID
NCT03040024
Protocol IDs
EU3268-16
NCI-2017-00172
IRB00086609
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
7.
A Randomized, Phase II Study of Ficlatuzumab with or without Cetuximab in Patients with Cetuximab-Resistant, Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Oral Cancer, Unknown Primary
NCI ID
NCT03422536
Protocol IDs
1710965268
NCI-2017-02209
AVEO
AV-299-17-117i
8.
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients with Incurable SCCHN
Cancer Type
Head and Neck Cancer, Oral Cancer
NCI ID
NCT02101034
Protocol IDs
201404139
NCI-2014-01079
14-X031
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.